Qiagen Expands QIAensemble Portfolio - Analyst Blog

By Zacks Equity Research,

Shutterstock photo

Qiagen ( QGEN">QGEN ), a major provider of innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions, recently introduced itsQIAensemble Decapper automation system.

This is an open platform system with which laboratories can eliminate many manual steps needed for the management of liquid-based cytology and other liquid vials. The rollout ofQIAensemble Decapper is underway in Europe and other parts of the world.

TheQIAensemble Decapper automation system, operated by an improved graphical user interface (GUI), is path-breaking as it will support downstream molecular testing while minimizing the chances of injuries to laboratory staff from repetitive motions. This system is compatible with sample racks on theQIAsymphony SP automation system.

Further, it regulates the processing with digital data collection and is flexible in regard to output tube types, such as conical tubes, u-shaped tubes, BDVacutainer tu bes andGreiner's Vacuette tubes.

Companion diagnostics are currently gaining significant traction and peers ofQiagen like Myriad Genetics ( MYGN">MYGN ) are establishing themselves as strong players in this market. However,Qiagen's long-term strategy involves technological advancement and new product introduction that can hugely increase its competitive advantage.

The company is constantly endeavoring for timely development and launch of products that address growing market needs. Currently, other than its next generation high throughput molecular testingQIAensemble product platform,Qiagen has several products underway like molecular medium-throughputQIAsymphony platform and related sample and assay technologies.

Moreover,Qiagen has historically expanded its reach and technological portfolio through acquisitions and is looking to ramp up investment in the future. The company's recent acquisitions of Australia-basedCellestis and France-basedIpsogen are expected to strengthenQiagen's leadership in molecular diagnostics, significantly expanding its profiling and personalized healthcare portfolios.

Additionally, we are also encouraged byQiagen's efforts on partnering with the pharmaceutical industry. In September 2011,Qiagen entered into a partnership with Eli Lilly ( LLY">LLY ) to jointly develop, manufacture and commercialize a molecular companion diagnostic for an early-stage investigational compound, which is currently being developed by Lilly. We strongly believe thatQiagen's aggressive acquisition and collaboration strategies will help drive growth in fiscal 2012 and beyond.  

Currently,Qiagen retains aZacks #3 Rank (short-term Hold). Over the long term, we remain Neutral on the stock.

LILLY ELI & CO ( LLY ): Free Stock Analysis Report
MYRIAD GENETICS ( MYGN ): Free Stock Analysis Report
QIAGEN NV ( QGEN ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Stocks
Referenced Stocks: LLY , MYGN , QGEN

More from Zacks.com




Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com